Feedback / Questions
SPK-7001 - Roche
Spark Therapeutics: Corporate Presentation
(Spark Therapeutics)
-
Nov 11, 2016 -
Anticipated initial efficacy analysis from P1/2 trial (NCT02341807) for choroideremia in early 2017
Anticipated P1/2 data
•
Inherited Retinal Dystrophy • Ophthalmology
http://ir.sparktx.com/phoenix.zhtml?c=253900&p=irol-presentations
Nov 11, 2016
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious